Introduction {#s1}
============

Natural killer (NK) cells play a central role in innate defenses against viruses and tumors. They belong to a family of innate lymphoid cells (ILC) that do not express receptors encoded by rearranged genes. NK cell function is regulated by an array of inhibitory and activating receptors. Inhibitory receptors that play a major role in the control of NK cell function are those specific for HLA-class (Cl)-I molecules. Killer Ig-like receptors (KIRs) recognize allotypic determinants shared by different HLA-Cl-I alleles, while CD94/NKG2A is specific for the non-classical HLA-E ([@B1]). The fact that NK cell inactivation is required to spare healthy cells implied the existence of activating receptors recognizing ligands on target cells. The prototypes and most important ones in tumor cell detection and killing are NKp46, NKp44, and NKp30, collectively called "natural cytotoxicity receptors" (NCRs) ([@B2]). While in an autologous setting all NK cells express one or more inhibitory receptors for self HLA-Cl-I, in an allogeneic setting, it may occur that KIRs expressed by a subset of NK cells do not recognize HLA-Cl-I alleles on allogeneic cells, and the lack of inhibition may result in killing of target cells ([@B3]). NK cells with these characteristics were named "alloreactive" NK cells. Although NK cells display a potent anti-tumor activity and are thought to participate to the control of tumor growth and metastatic spread, the tumor microenvironment may sharply inhibit their effector functions ([@B4], [@B5]). This inhibitory effect is due to the tumor cells themselves as well as to other cells present in the tumor microenvironment and frequently involves both the downregulation of activating surface receptors and the *de novo* expression of inhibitory checkpoints (primarily PD-1) ([@B6], [@B7]). In this contribution, we will briefly discuss different therapeutic strategies ([Table 1](#T1){ref-type="table"}), which allow to successfully exploit NK cell-mediated anti-tumor activity as well as novel promising approaches that may offer important new tools in cancer treatment.

###### 

Human NK cell-based immunotherapeutic approaches in tumors.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **1. Adoptive NK cell therapies**\
  - Infusion of IL-2- or IL-15-activated NK cells or lymphokine-activated lymphocytes (LAK and CIK) ([@B8]--[@B11]);\
  - Infusion of allogeneic "off-the-shelf" CAR-NK cells directed to tumor antigens ([@B12]).

  **2. NK cells in haplo-HSCT to cure high-risk leukemia**\
  - Transplant of "pure" donor CD34^+^ cells. NKG2A^+^ NK cells are detectable after 2 weeks, while KIR^+^, cytolytic NK cells only after 6--8 weeks. Central role of NK cells in GvL, especially of "alloreactive" NK cells ([@B13], [@B14]);\
  - Transplant of *αβ*T- and B cell-depleted mononuclear cells. Donor NK cells and *γδ*T cells, being present in the graft, are immediately available for the control of infections and leukemia relapses. Better clinical outcome, particularly in AML ([@B15]--[@B19]).

  **3.mAbs blocking inhibitory checkpoints in NK cells**\
  - The disruption of PD1/PD-L1 interactions unleashes both PD1^+^ T and NK cells. Major effect of NK cells in case of HLA-Cl-I^−^ tumors ([@B20]--[@B24]);\
  - Blocking of NKG2A expressed by both NK and tumor-infiltrating T cells results in killing of HLA-E^+^ tumors (i.e., most tumors) ([@B25], [@B26]);\
  - Combined blocking of NKG2A and PD1 in case of PD-L1^+^ tumors ([@B25], [@B26]);\
  - Combined use of NKG2A-blocking mAb and mAb specific for tumor antigens (e.g., EGFR): "unlocked" NK cells mediate ADCC ([@B25], [@B26]).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Boosting *in vivo* NK Cells With Immune Stimulatory Cytokines {#s2}
=============================================================

In cancer patients, NK cells frequently display an impaired function ([@B6], [@B27]). Thus, primary strategies in immunotherapy are aimed to boost *in vivo* NK cell-mediated antitumor activity. One approach is based on the *in vivo* administration of cytokines, such as IL-2 and IL-15, that determine NK cell activation, differentiation, and expansion ([@B8], [@B28]--[@B32]). IL-2 administration was approved in the 1990s for the treatment of metastatic RCC and melanoma patients ([@B33]--[@B35]). Two major obstacles in IL-2-based therapy are the dose-associated toxicity (primarily vascular leakage) and the induction of T regulatory (Treg) cell activation and expansion, thus resulting in inhibition of NK cell function ([@B9], [@B10]). Recently, IL-2 variants, with lower affinity for IL-2Rα subunit (highly expressed by Treg cells), have been designed ([@B11], [@B36], [@B37]). In addition, PEGylated IL-2 (also known as NKTR-214) that binds CD122 (IL-2Rβ), expressed by both T and NK cells, is able to boost preferentially these cells and their anti-tumor responses. This therapeutic treatment is currently under investigation in clinical trials for solid tumors ([@B13]). The use of IL-15 may represent a better therapeutic option as it can selectively sustain NK cells without inducing Treg expansion. However, the clinical use of IL-15 is limited because of its short *in vivo* half-life ([@B38]). Notably, IL-15 induces a rapid expansion of memory CD8^+^ T cells, thus favoring anti-tumor activity. The effect of IL-15 administration combined with checkpoint inhibitors (anti-CTLA-4 and/or anti-PD-1 mAbs) is currently under investigation in patients with cancers refractory to other therapies. To improve the anti-tumor effect of NK cells, ALT-803, an IL-15 superagonist complex, is also being assessed in phase I studies either alone ([@B14]) or in combination with checkpoint inhibitors ([@B39]). An emerging approach is based on bi- or tri-specific killer cell engagers (BiKEs and TriKEs) binding CD16 or NKG2D on NK cells and tumor antigens, thus favoring the interaction between NK cells and tumor cells. Notably, "TriKEs" also contain a modified IL-15 linker to improve NK cell survival and proliferation ([@B15], [@B40], [@B41]). An additional prospect is the use of IL-12, a molecule that enhances cytokine production and cytotoxicity by NK cells ([@B16]).

Adoptive Immunotherapy With Cytokine-Induced NK Cells {#s3}
=====================================================

Clinical trials have been attempted since 1980s in which NK cell-containing cell suspensions isolated from patients with metastatic melanomas were expanded *in vitro* in the presence of IL-2 and infused back into the patients. While a relevant effect was detected in some cases, primarily in metastatic lesions such as lung metastases, other tumor localizations were not affected. These studies were important because they provided the first evidence that such "lymphokine-activated killers" (LAK) could exert their anti-tumor effect also *in vivo*. Relevant toxicity was mostly related to the concomitant administration of high dosages of IL-2 ([@B17], [@B18]). Evolutions of such pioneering studies, based on adoptive cell therapy, were the use of IL-15 and, recently, the use of NK cells engineered with chimeric antigen receptor (CAR, see below). Although NK cells to be used in adoptive tumor therapy are usually derived from peripheral blood (PB), other sources have also been proposed. For example, the pleural fluid of primary or metastatic tumors contains high numbers of functional NK cells ([@B19]), which acquire strong cytotoxicity upon short culture intervals with IL-15 or IL-2 *in vitro*. Since large volumes of such fluids are routinely discarded, NK cells could be recovered and reinfused systemically or in the pleural cavity after *in vitro* culture with IL-15 ([@B8]). Such loco-regional treatment might contribute to the control of pleural localizations of the tumor. In general, the infusion of potent effector cells with anti-tumor activity is an important approach in tumor immunotherapy because it may greatly amplify the effect of endogenous cells. The relevance of infusing mature effector cells in cancer patients is also underscored in the αβT- and B-cell-depleted haploidentical hematopoietic stem cell transplantation (HSCT), in which leukemia relapses and infections are sharply reduced as compared to the HSCT setting with "purified" CD34^+^ cells, thanks to the co-infusion of mature γδT cells and NK cells (see below).

Role of NK Cells in the Therapy of High-Risk Leukemia in Haploidentical HSCT {#s4}
============================================================================

HSCT represents the life-saving therapy for acute leukemia poorly responsive to chemotherapy, relapsing, or with adverse cytogenetic characteristics. Unfortunately, it is possible to find a HLA compatible donor only for \~60% of patients ([@B42], [@B43]). Thus, T-depleted haplo-identical HSCT has been developed in an attempt to rescue those patients for whom no alternative therapeutic option is available. Haplo-HSCT is based on the infusion of "megadoses" of purified CD34^+^ cells extensively depleted of T cells in order to avoid life-threatening GvHD. In this transplantation setting, donor NK cells may express KIR that do not recognize any of the HLA-Cl-I alleles of the patient ([@B44], [@B45]). Notably, NK cells are the first donor lymphoid cells detectable in patients\' PB after transplantation. In pediatric patients, this occurs after \~2 weeks. However, such NK cells are represented by relatively immature CD56^bright^ cells, expressing NKG2A but not KIR (KIR expression is required for NK cell alloreactivity). Appearance of mature KIR^+^ NK cells requires an additional 4--6 weeks. In this T-depleted HSCT setting, NK cells play a major role in graft-vs.-leukemia (GvL) ([@B46]). The anti-leukemia effect has been related to NK cell alloreactivity in different studies, pioneered by Ruggeri et al., in adult AML ([@B20], [@B21], [@B45]). Indeed a clear correlation was found between the frequency of alloreactive NK cells and the clinical outcome ([@B22], [@B44]). Of note, a subset of NK cells derived from CMV-seropositive donors could undergo expansion in transplanted patients upon CMV reactivation after HSCT. These NK cells expressed NKG2C, CD57, and displayed epigenetic modifications identical to those present in memory T cells. These characteristics confer to NK cells a strong cytolytic activity, including a "memory-like" behavior in response to NKG2C triggering, and are associated to a better clinical outcome ([@B23]--[@B25], [@B47], [@B48]). In pediatric patients receiving "megadoses" of purified CD34^+^, the survival probability at 5 years was very good for patients with high-risk ALL, reaching over 70% in the presence of NK alloreactivity and \~40% in its absence, the overall survival being \~60%. In patients with AML, survival reached \~40% in case of NK alloreactivity, but only \~20% in its absence, the overall survival being \~30%. Notably, all deaths occurred early, during the first few weeks/months after transplant, primarily due to leukemia relapses or infections ([@B20], [@B49]). In an attempt to fill the temporal gap between transplant and the generation of mature KIR^+^ alloreactive NK cells, a novel graft manipulation has been developed. This is based on the selective depletion of TCR αβ T cells (responsible of GvHD) and B cells (to prevent B cell malignancies in immunocompromised individuals). With this graft manipulation, the infused mononuclear cells also contain, in addition to HSC (including not only CD34^+^ but also CD34^−^ precursors), effector cells such as mature (CD56^dim^) NK cells and TCRγδ T cells, both capable of anti-leukemia activity ([@B12], [@B26], [@B50]). In addition, the graft contained different myeloid cell types, including monocytes and low-density monocytic or polymorphonuclear (PMN) myeloid cells ([@B51], [@B52]). The immediate availability of cells capable of killing leukemia blasts and controlling virus reactivation or infections had a major positive impact. Indeed the overall survival probability was \~70% not only for ALL but also for AML patients. An unexpected finding was that NK cell-mediated alloreactivity did not appear to play a significant role ([@B49]). While it is conceivable that the NK cell function may be offset by a predominant GvL effect of γδT cells (greatly expanded *in vivo* thanks to the use of zoledronic acid) ([@B53]), we could not exclude that also other mechanisms may impair NK alloreactivity. Indeed we recently found that myeloid-derived suppressor cells (MDSC), particularly abundant in the graft, exert a potent inhibitory effect on NK cell function ([@B54]). These data suggest a possible effect also *in vivo* and offer a clue for applying an additional step in the graft manipulation to further remove MDSC. The rescue of NK cell function may contribute to increase the clinical outcome, particularly by preventing leukemia relapses, still representing \~25% of total deaths.

Taken together, these data support the notion that NK and other cells of the innate immunity may play a relevant role in the therapy of high-risk leukemia. Notably, HSC from different sources give rise to other innate lymphoid cells (ILC), particularly ILC3. ILC3 cells contribute to tissue repair and regeneration of lymphoid tissues and are likely to play a major role in the integrity of such tissues severely compromised by the chemo/radiotherapy given to patients prior to HSCT ([@B55]).

Blocking of Inhibitory Checkpoints/Receptors to Unleash NK Cells {#s5}
================================================================

NK cells express inhibitory receptors such as the HLA-Cl-I-specific KIRs and CD94/NKG2A that may function as true inhibitory checkpoints ([@B56]). The lack of interactions with their cognate HLA class I ligands on target cells leads to cytolytic activity and cytokine production. This may occur in an autologous environment in the case of tumors or viral infections, as well as in an allogeneic setting such as the haplo-HSCT (see above).

While KIRs and NKG2A are constitutively expressed by mature NK cells, the expression of other inhibitory checkpoints involved in the homeostasis of immune responses, including PD-1, TIGIT, TIM-3, and CD96, is inducible ([@B57]). Such *de novo*-expressed checkpoint regulators have been shown to inhibit the NK cell function upon interaction with their ligands on tumor cells ([@B19], [@B58]). We will focus on PD-1 since it is a major checkpoint receptor involved in the control of immune responses, and the therapeutic use of blocking antibodies disrupting the PD-1/PD-L1 axis represents a major breakthrough in the cure of highly aggressive tumors.

While PD-1 expression has been first reported in T lymphocytes, recent studies revealed that, in pathological conditions, such as CMV infections and tumors, it may be expressed also by NK cells. The expression of PD-1 by NK cells is controversial; indeed PB-NK cells derived from both healthy donors (HD) and neoplastic patients were originally reported to express low levels, if any, of PD-1. On the other hand, PD-1^bright^ NK cells were found in the PB and, more abundantly, in ascitic fluid of ovarian carcinoma patients ([@B58]), as well as in pleural effusions of patients with primary and metastatic tumors ([@B19]) and in Hodgkin lymphoma. Notably, both PD-1 mRNA and PD-1 protein are present in the cytoplasm of NK cells isolated from HD ([@B59]), although the molecular mechanisms leading to its surface expression are still poorly defined.

Under physiological conditions, PD-1 acts as a brake in the regulation of immune responses, playing a relevant role in the induction and maintenance of T cell tolerance. However, in cancer patients, it may impair T cell- and NK cell-mediated responses against tumor cells. In these cases, immunotherapy with mAbs disrupting the PD-1/PD-L1 interaction has shown great effectiveness, particularly in melanoma and lung carcinomas with responses to therapy reaching 20--40% in different clinical trials. Importantly, therapeutic blockade of inhibitory checkpoints in NK cells may be effective also in HLA-Cl-I^neg^ tumors, a condition that frequently occurs in metastatic carcinomas (as a result of tumor escape from cytolytic T cell-mediated control) ([@B60], [@B61]). Nevertheless, the majority of patients do not benefit from the anti-PD-1/PD-L1 treatment. Thus, prediction of clinical responses to PD-1/PD-L1 blockade represents a major issue also in view of important side effects and of the high treatment cost. In this context, an important approach is the evaluation of PD-L1 expression on tumor cells. However, its predictive value is still unsatisfactory due to several technical limitations, such as the use of different mAbs, different diagnostic materials (biopsies vs. surgical specimen, cytology), and different operators ([@B62]--[@B64]). For this reason, current researches are aimed to identify additional checkpoints to be targeted, either alone or in combination. In this context, the actual potential of blocking TIGIT, TIM-3, CD96, or LAG-3 is currently under investigation. Importantly, a recent study by Vivier\'s group has highlighted the use of anti-CD94/NKG2A blocking mAb in tumor therapy ([@B65]). NKG2A^+^ cells represent \>50% of PB-NK cells and may express either the CD56^bright^ or the CD56^dim^ phenotype. While CD56^bright^ NKG2A^+^ NK cells are primarily cytokine producers, CD56^dim^ NKG2A^+^ cells also display potent cytolytic activity and DC editing capability ([@B66]). NKG2A is also expressed by T lymphocytes, either upon prolonged stimulation via TCR ([@B67]) or upon exposure to TGF- β ([@B68]), an immunosuppressive cytokine often present in the tumor microenvironment. This *de novo* NKG2A expression may lead to the impairment of T cell function, including anti-tumor activity ([@B67]). Accordingly, blocking of NKG2A can unleash not only NK cells but also tumor-infiltrating T cells with potential anti-tumor activity. In addition, HLA-E, the NKG2A ligand, is expressed in many highly aggressive tumors (e.g., lung, head and neck, colon, pancreas, and liver), and most cells in the tumor are HLA-E^+^. Accordingly, blocking of NKG2A may result in potent anti-tumor effect in different cancers. In tumors expressing both HLA-E and PD-L1, the combined blocking of NKG2A and PD-1/PD-L1 axis can enhance NK cell cytotoxicity and rescue T cell function. Notably, in a murine model, this combined treatment also resulted in T cell proliferation and T cell memory induction. Finally, in HLA-E^+^ tumors, expressing tumor-associated antigens, NKG2A blockade could increase the therapeutic efficacy of other mAbs (for example, anti-EGFR mAb), favoring the NK cell triggering via the CD16-mediated antibody-dependent cytotoxicity (ADCC) ([@B65], [@B69]). These different scenarios involving NKG2A blockade are promising because they may occur in many tumors and involve important synergies with other checkpoint inhibitors or therapeutic antibodies directed to tumor antigens. In addition, these studies emphasize the importance of harnessing NK cell-mediated anti-tumor activity while, so far, the immunotherapeutic strategies have been mostly focused on potentiating T cell anti-tumor responses.

Concluding Remarks {#s6}
==================

It is now clear that cells of the innate immunity, in particular NK cells, play a relevant defensive role in the control of tumor growth and metastases. As shown by many experimental evidences, both *in vitro* and *in vivo*, such anti-tumor effect is related both to direct cytolytic activity and to the production of cytokines that activate other effector cells and promote useful TH1 adaptive responses. Therefore, therapeutic approaches that trigger and/or reconstitute NK cell function and proliferation are crucial in tumor immunotherapy. In addition, NK cells engineered with CAR, targeting tumor antigens, are highly promising. Indeed CAR-NK cells could complement or even replace CAR-T cells in view of their particularly potent cytolytic activity and their peculiar homing capability ([@B70]--[@B72]). Importantly, in case of loss of the targeted tumor antigen, CAR-NK cells could still exert their anti-tumor activity, particularly in the absence of KIR/HLA ligand matching. In addition, CAR-NK cells, genetically modified to over-express either molecules mediating tumor killing or cytokines able to sustain NK cell proliferation/function (e.g., IL-15), may represent a further valuable tool for adoptive cell therapy of cancer ([@B73], [@B74]). Notably, since NK cells do not cause GvHD, they may be obtained from unrelated donors, thus overcoming major limitations of autologous T cell therapy (time needed for preparation and high costs) and providing a rapid access to an "off-the-shelf" life-saving therapy. Indeed given the possibility to better plan treatments with standardized approaches and appropriate cell numbers, donor-derived allogeneic CAR-NK cells may represent the next generation of cell-based therapies of cancer. [Table 2](#T2){ref-type="table"} summarizes recent or ongoing clinical trials based on the use of adoptively infused NK cells.

###### 

Selected recent/ongoing trials of NK-based adoptive therapy of cancer.

  **Identifier**   **Trial**                                                                                                                                                          **Status**               **Phase**   **NK cells/drug**                                                                                                    **Tumor**
  ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------ ----------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NCT00900809      QUILT-3.018: Neukoplast™ (NK-92) for the treatment of refractory or relapsed acute myeloid leukemia                                                                Recruitment completed    I           NK-92                                                                                                                Acute myeloid leukemia
  NCT03027128      QUILT-3.028: study of haNK™ for infusion in subjects with metastatic or locally advanced solid tumors                                                              Recruitment completed    I           NK-92                                                                                                                Solid tumor
  NCT03383978      Intracranial injection of NK-92/5.28.z cells in patients with recurrent HER2-positive glioblastoma (CAR2BRAIN)                                                     Recruiting               I           NK-92/5.28.z                                                                                                         Glioblastoma
  NCT02573896      Immunotherapy of relapsed refractory neuroblastoma with expanded NK cells                                                                                          Recruiting               I           CAR-NK-Ch14.18 lenalidomide                                                                                          Neuroblastoma
  NCT02280525      Cord blood Natural Killer (NK) cells in leukemia/lymphoma                                                                                                          Active, not recruiting   I           NK Cells, lenalidomide, rituximab (anti-CD20), fludarabine, cyclophosphamide, cytarabine                             Leukemia
  NCT02481934      Clinical trial of expanded and activated autologous NK cells to treat multiple myeloma (NK-VS-MM)                                                                  Completed                I           NK Cells, lenalidomide, bortezomib                                                                                   Multiple myeloma
  NCT03415100      Pilot study of NKG2D-ligand targeted CAR-NK cells in patients with metastatic solid tumors                                                                         Recruiting               I           CAR-NK cells targeting NKG2D ligands                                                                                 Solid tumors
  NCT01974479      Pilot study of redirected haploidentical natural killer cell infusions for B-lineage acute lymphoblastic leukemia                                                  Suspended                I           Anti-CD19 redirected NK cells                                                                                        B-cell acute lymphoblastic leukemia
  NCT03579927      CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood NK cells, high-dose chemotherapy, and stem cell transplant in treating participants with B-cell lymphoma   Not yet recruiting       I/II        Cord blood-NK Cells Autologous HSCT carmustine Cytarabine, etoposide, filgrastim, melphalan, rituximab (anti-CD20)   CD19 positive, mantle cell lymphoma, recurrent diffuse large B-cell lymphoma, recurrent follicular lymphoma, refractory B-cell non-Hodgkin lymphoma, refractory diffuse large B-Cell lymphoma, refractory follicular lymphoma
  NCT03056339      Umbilical and Cord Blood (CB) derived CAR-engineered NK cells for B lymphoid malignancies                                                                          Recruiting               I/II        iC9/CAR.19/IL15 transduced CB-NK Cells, fludarabine, cyclophosphamide, mesna, AP1903                                 B-lymphoid malignancies, acute lymphocytic leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma
  NCT02839954      CAR-pNK cell immunotherapy in MUC1 positive relapsed or refractory solid tumor                                                                                     Unknown                  I/II        Anti-MUC1 CAR-NK cells                                                                                               Hepatocellular carcinoma, NSCLc, pancreatic carcinoma, triple-negative invasive breast carcinoma, malignant glioma of brain, colorectal carcinoma, gastric carcinoma
  NCT02892695      PCAR-119 bridge immunotherapy prior to stem cell transplant in treating patients with CD19 positive leukemia and lymphoma                                          Unknown                  I/II        Anti-CD19 CAR-NK cells                                                                                               Acute/chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, B-cell prolymphocytic leukemia, diffuse large cell lymphoma
  NCT02742727      CAR-pNK cell immunotherapy in CD7 positive leukemia and lymphoma                                                                                                   Unknown                  I/II        Anti-CD7 CAR-NK cells                                                                                                Acute myeloid leukemia, precursor T-cell lymphoblastic leukemia-lymphoma, T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, extranodal NK/T-cell lymphoma, nasal type enteropathy-type intestinal T-cell lymphoma
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